Segall Bryant & Hamill LLC Acquires Shares of 20,802 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Segall Bryant & Hamill LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,802 shares of the company's stock, valued at approximately $8,600,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $25,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Remove Ads

IDEXX Laboratories Stock Down 1.6 %

Shares of NASDAQ IDXX traded down $6.67 during midday trading on Friday, hitting $415.87. 470,167 shares of the stock traded hands, compared to its average volume of 581,913. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The business has a 50 day moving average price of $437.07 and a two-hundred day moving average price of $443.27. The company has a market cap of $33.71 billion, a PE ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IDXX. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.